Compare Kroger Co (KR) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Kroger Co vs TG Therapeutics Inc — how do they compare? Kroger Co trades at $56.01 (market cap $34.46B), while TG Therapeutics Inc trades at $49.44 (market cap $7.64B). The key difference: Kroger Co is far larger — about 4.5× TG Therapeutics Inc's market cap, and Kroger Co pays a 2.56% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals.
| KR | TGTX | |
|---|---|---|
Market Cap | $34.46B | $7.64B |
Sector | Consumer Staples | Health |
52-Week High | $75.60 | $59.06 |
52-Week Low | $55.53 | $26.94 |
Enterprise Value | $54.56B | $7.84B |
Dividend Yield | 2.56% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Kroger (KR) trades at $56.09, down 0.69% on the day, with a bearish technical signal from moving averages. The company reported mixed Q1 2026 earnings, missing EPS estimates by $0.01, but beat in the prior two quarters. Revenue for 2025 was $147.12 billion with a net income margin of 0.71%. Recent news includes the appointment of a new Chief eCommerce Officer and expanded prescription delivery services, signaling digital growth initiatives.
The stock presents a valuation gap with a consensus price target of $68.25, implying 22% upside, supported by a 47.7% buy rating from analysts. However, risks include competitive pressures in grocery retail, a high P/E ratio of 32.89, and a projected net income decline in 2026. Positive cash flow trends and dividend payments offer stability, but execution on e-commerce strategy is critical for sustained growth.
TG Therapeutics (TGTX) trades at $49.50, up 0.69% today, with a bearish technical signal from moving averages despite neutral oscillators. The company reported strong revenue growth, with Q2 2026 sales reaching $240 million and raised full-year guidance to $950 million, though it missed earnings estimates for three consecutive quarters. Profitability metrics remain robust with a net income margin of 55.22% and ROE exceeding 100%, but valuation ratios like EV/EBITDA at 56.26 suggest premium pricing.
The outlook is mixed: bullish analyst sentiment with an 84.6% buy rating and a $63.75 price target offers upside potential, driven by Briumvi's commercial success and expansion into schizophrenia trials. However, risks include earnings misses, a shareholder investigation into fiduciary duties, and high cash burn in 2025. Investors should weigh strong revenue momentum against execution risks and elevated valuations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Kroger Co
Kroger is the leading American grocer, with 2,726 supermarkets operating under several banners throughout the country as of the end of fiscal 2021. Around 83% of stores have pharmacies, while nearly 60% also sell fuel. The company also operates roughly 120 fine jewelry stores. Kroger features a leading private-label offering and manufactures around 30% of its own-brand units (and more than 40% of its grocery own-label assortment) itself, in 33 food production plants nationwide. Kroger is a top-two grocer in most of its major markets (as of early 2021, according to company data). Virtually all of Kroger's sales come from the United States.
Read more on KR →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
